Lysosomal storage disorders (LSDs) result from an enzyme deficiency within lysosomes. The systemic administration of the missing enzyme, however, is not effective in the case of LSDs with central nervous system (CNS)-involvement. Here, an enzyme delivery system based on the encapsulation of cross-linked enzyme aggregates (CLEAs) into poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) functionalized with brain targeting peptides (Ang2, g7 or Tf2) is demonstrated for Krabbe disease, a neurodegenerative LSD caused by galactosylceramidase (GALC) deficiency. We first synthesize and characterize Ang2-, g7- and Tf2-targeted GALC CLEA NPs. We study NP cell trafficking and capability to reinstate enzymatic activity in vitro. Then, we successfully test our formulations in the Twitcher mouse. We report enzymatic activity measurements in the nervous system and in accumulation districts upon intraperitoneal injections, demonstrating activity recovery in the brain up to the unaffected mice level. Together, these results open new therapeutic perspectives for all LSDs with major CNS-involvement.
|Titolo:||Brain-targeted enzyme loaded nanoparticles: a breach through the blood brain barrier for enzyme replacement therapy in Krabbe disease|
|Editore:||American Association for the Advancement of Science|
|Data di pubblicazione:||1-nov-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1126/sciadv.aax7462|
|Parole chiave (inglese):||Biophysics|
|Appare nelle tipologie:||1.1 Articolo in rivista|